TrialScout™ announced today that hyperCORE International has joined its powerful and dynamic platform that aims to help patients find clinical trials and choose the research site that is right for them
BUFFALO, N.Y., Oct. 10, 2019 /PRNewswire/ -- TrialScout™ announced today that hyperCORE International has joined its powerful and dynamic platform that aims to help patients find clinical trials and choose the research site that is right for them. TrialScout™ provides objective ratings and reviews from previous participants on their clinical trial experiences. hyperCORE International is a super network of highly experienced research sites. They are one of the largest integrated research organization’s (IRO’s) globally. “We are thrilled to have hyperCORE International join TrialScout,” said Dr. Irfan Khan, CEO of Circuit Clinical™. “This partnership gives TrialScout an international reach a year ahead of schedule with one of the most innovative IRO partners. Our team is dedicated to ensuring that patients voices are shared, to help provide peer-to-peer decision support to potentially new trial participants. TrialScout help sites develop and implement ways to reduce patient dropout through service recovery.” hyperCORE International network to date, is a collaboration of eight companies which collectively has more than 81 active research sites across the globe. Two hyperCORE members IACT Health and LMC Manna Research have already completed onboarding and will benefit from TrialScout’s ratings and reviews, preferential search and experiential analytics. TrialScout is now able to provide their sites with a deep set of analytics to help with site optimization. hyperCORE is the first network to collaborate on the TrialScout platform. “hyperCORE’s commitment to improving the patient experience is further enhanced by TrialScout’s platform as it provides an immediate feedback mechanism previously unavailable. This allows us to incorporate the patient’s voice more authentically and intimately, thus helping hyperCORE International drive meaningful change that is desperately needed in clinical research,” said Mark Lacy, CEO of hyperCORE International. About TrialScout™ About hyperCORE International hyperCORE International is committed to the highest standard of research excellence with subject safety, data integrity, rapid study startup, competitive enrollment, and outstanding subject retention as top priorities. Its members have won numerous awards for performance, quality, and innovation. Learn more at www.hyperCOREinternational.com
Contact: Rachael Pollinger, TrialScout
SOURCE TrialScout |